Q-omics provides the consensus-scored NPM1P30 profile across patient tissues and cancer cell-line models. NPM1P30 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NPM1P30 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, NPM1P30 RNA expression shows 6,905 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, COAD, and GBM as cancer lineages where NPM1P30 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPM1P30 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPM1P30 survival associations across molecular data types. NPM1P30 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPM1P30 RNA expression–survival associations across cancer types. High NPM1P30 expression shows unfavorable associations in LIHC, OV, LUSC and KIRC, but favorable associations in COAD and GBM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LIHC as the clearest survival context for NPM1P30 RNA expression.
This table summarizes NPM1P30 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NPM1P30. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPM1P30 shows lower tumor expression in THCA and higher tumor expression in COAD, UCEC, LUSC and HNSC. The COAD box plot shows higher NPM1P30 RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p = .021).
This table shows molecular features associated with NPM1P30 in patient tissues and cancer cell lines. In patient samples, NPM1P30 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
